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INTRODUCTION

The 510(k) application process for approving lower-risk medical devices
under the Food and Drug Administration (FDA)1 has recently come under
criticism for its lack of adequately measuring the safety and effectiveness of
medical devices.2 To remedy this situation, the FDA created a taskforce to study
the current 510(k) system.3
This taskforce recently submitted its
recommendations to the FDA as to what changes need to be made to increase the
effectiveness of the 510(k) application process.4
The regulation of medical devices came into effect with the Medical Device
Amendments of 1976 (MDA).5 These amendments were passed to encourage the
research and development of medical devices but also “to protect the public from
harm caused by the use of medical devices.”6 The MDA created the system of
premarket approval for medical devices.7 It also created an exception whereby
devices that could claim substantial equivalence to an already legally marketed
device did not have to undergo the premarket approval process.8 This exception
is currently referred to as the 510(k) approval process.
The goal of this note is to examine how the proposed changes to the 510(k)
system may affect future patent litigation. This will be done by examining the
background of the FDA approval process in detail and then exploring the changes
that have been proposed to the 510(k) process. Next, this article will examine
how the 510(k) approval process affected determinations of patent validity and
patent infringement claims in the past. Finally, this article will analyze how the
proposed changes to the 510(k) approval process may affect patent validity and
patent infringement claims going forward.

1

21 U.S.C. § 360e (2006).
Letter from Jeffrey Shuren, Dir., Ctr. for Devices & Radiological Health, FDA, to the
American
Public
(on
file
with
the
FDA),
available
at
http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDRH/CDRHReports/UCM239451.pd
f.
3
Id.
4
COMM. ON THE PUB. HEALTH EFFECTIVENESS OF THE FDA 510(K) CLEARANCE PROCESS,
INST. OF MED., MEDICAL DEVICES AND THE PUBLIC’S HEALTH: THE FDA 510(K) CLEARANCE
PROCESS AT 35 YEARS 1 (2011) [hereinafter Committee on Effectiveness of 510(k) Process].
5
Medical Device Amendments of 1976, Pub. L. No. 94-295, 90 Stat. 539 (codified as amended
at 21 U.S.C. §§ 301–392 (2006)).
6
William Stute, Note: Federal Preemption and the Medical Device Amendments: Medtronic,
Inc. v. Lohr, 116 S. Ct. 2240 (1996), 23 WM. MITCHELL L. REV. 949, 956 (1997).
7
21 U.S.C. § 360e (2006).
8
See id. § 360e(b)(1)(B).
2
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BACKGROUND TO THE FDA MEDICAL DEVICE APPROVAL PROCESS

This section sets out how the FDA regulates medical device manufacturers,
looking specifically at how it approves medical devices based upon their risk
level. Medical devices are put into one of three classes based upon the level of
risk they pose to the patient.
A.

Medical Device Regulatory Classification System

The FDA established three different regulatory classes for medical devices9
dependent upon the level of control necessary to determine their safety and
effectiveness.10 Medical devices that are given a Class I status consist of low-risk
medical devices which require only general control under the FDA.11 The
standard of general control is applied to all medical devices and requires medical
device manufacturers to follow basic regulations to ensure the safety and
effectiveness of their medical devices.12 Medical devices can be given Class I
status in two different ways. The first is if the device is not represented for use as
a life supporting or life-saving means, or is needed to prevent impairment of
human health.13 The second is if the device “does not present a potential
unreasonable risk of illness or injury.”14
Medical devices that are given Class II status are moderate-risk devices that
require both general controls and special controls.15 Special controls are supposed
to provide assurance of the safety and effectiveness of the device. 16 Special
controls for Class II status medical devices include “promulgation of performance
standards, postmarket surveillance, patient registries, development and
dissemination of guidelines . . . recommendations, and other appropriate actions
as the Secretary deems necessary . . . .”17
9

21 U.S.C. § 360c (2006).
U.S. Food and Drug Admin., Device Classification,
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/ClassifyYourDevic
e/default.htm [hereinafter Device Classification] (last updated Apr. 27, 2009).
11
See 21 U.S.C. § 360c(a)(1)(A) (2006).
12
See id. § 360c(a)(1)(A)(i); U.S. Food and Drug Admin., General Controls for Medical
Devices,
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/GeneralandSpecial
Controls/ucm055910.htm (last updated May 13, 2009).
13
21 U.S.C. § 360c(a)(1)(A)(ii)(I) (2006).
14
Id. § 360c(a)(1)(A)(ii)(II).
15
Id. § 360c(a)(1)(B).
16
Id.; see also U.S. Food and Drug Admin., General and Special Controls,
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/GeneralandSpecial
Controls/default.htm (last updated Apr. 23, 2009).
17
21 U.S.C. § 360c(a)(1)(B) (2006).
10
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Medical devices that are given Class III status are high-risk medical devices
that require both general controls and premarket approval.18 Premarket approval
is a complex and comprehensive system for proving the safety and effectiveness
of devices that are purported for use in supporting or sustaining human life, or
devices that may present unreasonable risks of illness or injury.19 The
requirements for obtaining premarket approval are set forth in 21 U.S.C. § 360e.20
As such, the regulatory class is generally dispositive of the manner in which
the FDA approves a medical device for marketing.21 Class I and Class II medical
devices may be exempt from any approval process if they are either preamendment devices that have not been significantly changed or modified, or if
they are specifically exempt by regulation.22 Otherwise, Class I and Class II
medical devices must be approved for market by the FDA through the submission
of a 510(k) application.23 Class III medical devices must be approved under a
Premarket Approval application, unless the device is a preamendment device and
premarket approval has not been called for.24
B.

Background of the 510(k) Process

The 510(k) process of approving a medical device is a quicker and less
demanding way to bring a device to market as compared to the premarket
approval process. The main goals of the 510(k) program are to facilitate
innovation by allowing medical devices to come to market faster, while ensuring
that all medical devices are safe and effective.25 The 510(k) program requires that
18

See id. § 360c(a)(1)(C).
Id.
20
(2006); see also U.S. Food and Drug Admin., Premarket Approval (PMA),
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/Pr
emarketSubmissions/PremarketApprovalPMA/default.htm [hereinafter Premarket Approval] (last
updated Jan. 24, 2012).
21
See Premarket Approval, supra note 20.
22
U.S.
Food
and
Drug
Admin.,
Class
I/II
Exemptions,
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/ClassifyYourDevic
e/ucm051549.htm (last updated May 13, 2009). Preamendment devices refer to devices that had
been marketed in the U.S. prior to the Medical Device Amendments of 1976. Id. The Medical
Device Amendments were intended to give the FDA authority over the approval of medical
devices depending on their safety and effectiveness. See Medical Device Amendments of 1976,
supra note 5.
23
21 U.S.C. § 360e (2006); see also Device Classification, supra note 10.
24
Device Classification, supra note 10.
25
U.S. Food and Drug Admin., 510(k) and Science Report Recommendations: Summary and
Overview of Comments and Next Steps, 1 (2011) [hereinafter 510(k) and Science Report
Recommendations],
http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDRH/CDRHReports/UCM239449.pd
f (last visited Apr. 18, 2012).
19
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all Class I and Class II medical device manufacturers (except those that are
exempt) submit their 510(k) application ninety days before they plan on bringing
their product to market.26
Under the current regulations, a 510(k) submission should include basic
information about the device including the name of the device, what class the
device falls within, and information about the company marketing the device. 27 A
submission must include information that will be used to market the device,
including proposed labeling and advertising materials.28 Title 21 of the Code of
Federal Regulations states in section 807.87(e) that “[w]here applicable,
photographs or engineering drawings should be supplied.”29 One must also
include a brief description of the device, including an explanation of how the
device functions, the scientific concepts that form the basis for the device, and the
significant physical and performance characteristics of the device which may
include what materials are used to manufacture the device, the physical properties
of the device, and the design of the device.30
One must also include a statement of substantial equivalence to a predicate
device in the form of “a statement indicating the device is similar to and/or
different from other products of comparable type in commercial distribution,
accompanied by data to support the statement.”31 This means direct comparison
of the proposed medical device to the “predicate [device]”, to which the 510(k)
submission is claiming equivalence.32
C. Confidentiality of the 510(k) Application
The FDA lists the name, manufacturer, and the 510(k) summary of all
approved 510(k) applications on their website within a month of their approval.33
26

21 C.F.R. § 807.81 (2012).
21 C.F.R. § 807.87(a)–(d) (2012); see also U.S. Food and Drug Admin., Content of a 510(k),
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/Pr
emarketSubmissions/PremarketNotification510k/ucm142651.htm [hereinafter Content of a
510(k)] (last updated Mar. 15, 2012) (listing other elements required to ensure that the 510(k) is
complete).
28
21 C.F.R. § 807.87(e) (2012).
29
Id.
30
Id. § 807.92(a)(4).
31
Id. § 807.87(f).
32
Id. § 807.92(a)(3).
33
U.S.
Food
and
Drug
Admin.,
510(k)
Clearances,
http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearan
ces/510kClearances/default.htm [hereinafter 510(k) Clearances] (last visited Mar. 24, 2012); see,
e.g.,
U.S.
Food
and
Drug
Admin.,
January
2011
510(k)
Clearances,
http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearan
ces/510kClearances/ucm242640.htm (last updated Apr. 21, 2011).
27
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Typically, all medical devices that are approved are listed on the FDA’s website
unless the 510(k) application can be deemed confidential.34 A medical device
510(k) application can be deemed confidential if the device is not on the market
and it has been made clear that the manufacturer does not intend to market the
device within ninety days of the 510(k) submission.35 To ensure confidentiality
one must request that the 510(k) application be kept confidential by stating that no
notification has been made to anyone about the intent to someday market the
device, and the commissioner must agree that the intent to market the device
should be kept as confidential commercial information.36
III.

PROPOSED CHANGES TO THE 510(K) PROCESS

The 510(k) process has come under criticism lately for not being a sound
system to approve devices for market.37 The 510(k) system works by evaluating a
medical device’s safety and effectiveness by comparing the new medical device
to another medical device that is considered a substantial equivalent of the new
medical device.38 Thus, a medical device may be approved under the 510(k)
system if it could be deemed substantially equivalent to another medical device
that was also approved under the 510(k) system, ad infinitum. This leads to a
situation where a medical device that is approved through a 510(k) application
may be based upon a substantially equivalent medical device that was on the
market prior to 1976, and as such has never been approved by the FDA.39
In August 2010, the FDA’s Center for Devices and Radiological Health
(CDRH) released the preliminary reports from their 510(k) Working Group that
was established to review the 510(k) process and propose changes to the
program.40 The FDA also asked the Institute of Medicine (IOM) to create a task
force to review the 510(k) system as an outside party. The IOM created the
Committee on the Public-Health Effectiveness of the FDA 510(k) Clearance
Process and released their recommendations to the FDA in July 2011.41

34

See 510(k) Clearances, supra note 33.
21 C.F.R. § 807.95(b) (2012).
36
Id. §§ 807.95(b)(1)-(2).
37
See, e.g., Letter from Jeffrey Shuren, supra note 2, at 1.
38
See 21 C.F.R. §§ 807.87(j) (2012); see also Content of a 510(k), supra note 27.
39
David R. Challoner & William W. Vodra, Medical Devices and Health — Creating a New
Regulatory Framework for Moderate-Risk Devices, 365 NEW ENG. J. MED. 977, 978 (2011),
available at http://www.nejm.org/doi/full/10.1056/NEJMp1109150.
40
510(k) and Science Report Recommendations, supra note 25, at 1.
41
Committee on Effectiveness of 510(k) Process, supra note 4, at 3.
35
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The Institute of Medicine’s Recommendations

A.

In a letter from David Challoner42 to Jeffrey Shuren43 sent July 20, 2011, the
IOM stated it was their opinion that the 510(k) process “generally is not intended
to evaluate the safety and effectiveness of medical devices and, furthermore,
cannot be transformed into a premarket evaluation of safety and effectiveness.”44
Thus, IOM’s recommendations focused not on what changes should be made to
the 510(k) system but rather on what changes need to be made overall to develop
a more rational regulatory framework for medical devices.45
The IOM’s report concluded that the 510(k) process lacks the legal basis to be
a reliable premarket screen of the safety and effectiveness of moderate-risk
devices.46 The IOM also focused on the fact that the postmarket surveillance
which should be required for medical devices is basically nonexistent under the
current 510(k) system.47 The IOM suggested that the FDA work to develop a new
framework for an integrated pre-market and post-market regulatory system that
would focus more intently on the safety and effectiveness of each device
throughout its life cycle.48 The IOM suggested that the new regulatory system
utilize the following six criteria:
[B]e based on sound science; be clear, predictable, straightforward,
and fair; be self-sustaining and self-improving; facilitate
innovation that improves public health by making medical devices
available in a timely manner and ensuring their safety and
effectiveness throughout their lifecycle; use relevant and
appropriate regulatory authorities and standards throughout the life
cycle of devices to ensure safety and effectiveness; and be riskbased.49
Overview of FDA’s Proposed Changes

B.

In the preliminary reports released in August 2010, the FDA’s Task Force and
Working Group suggested fifty-five changes to improve the 510(k) program and
42

Chair for the Committee on the Public-Health Effectiveness of the FDA 510(k) Clearance
Process
43
Director of Center for Devices & Radiological Health
44
Letter from David Challoner, Chair, Comm. on the Public-Health Effectiveness of the FDA
510(k) Clearance Process, Inst. of Med., to Jeffrey Shuren, Dir., Ctr. for Devices & Radiological
Health, Food and Drug Admin. (July 20, 2011) (on file with IOM).
45
Id. at 2.
46
Committee on Effectiveness of 510(k) Process, supra note 4, at 3.
47
Id.
48
Id.
49
Id.
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use of science.50 The FDA stated in its report, 510(k) and Science Report
Recommendations, that it planned to implement a portion of the report’s
recommendations in 2011 by taking twenty-five actions which it laid out in its
Plan of Action included in the report.51 The recommendations that will be
implemented first will be those that foster innovation, enhance regulatory
predictability, and improve patient safety.52
The changes that will be
implemented include issuing guidance to provide greater clarity about the 510(k)
program and improving training for CDRH staff and industry. 53 In January 2012,
the FDA published a list of the accomplishments they had made under their
510(k) Plan of Action.54 The changes that the FDA plans to make that may affect
the area of patent law are further discussed below.
1. Adoption of the Use of an “Assurance Case” Framework for 510(k)
Submissions
An assurance case is a formal method to prove the validity of a particular
claim by a party submitting a convincing argument along with supporting
evidence.55 Implementing an assurance case framework for 510(k) applications
would mean that all information that is submitted to the FDA concerning the
description of the device and the intended use of the product would need to be
submitted in a more detailed section of the 510(k) application.56 Using an
assurance case framework would mean that each 510(k) submission would be
held to a higher level of completeness and it may prevent early submissions that
take too long to correct, thus burdening the FDA review process. To begin to
implement this suggestion, the FDA began a pilot program to study the use of an
assurance framework for infusion pumps57 to determine whether an assurance
case framework should be broadly applied.58

50

510(k) and Science Report Recommendations, supra note 25, at 3.
Id.
52
Id. at 2.
53
Id.
54
U.S. Food and Drug Admin., CDRH Plan of Action for 510(k) and Science, 1 (2012)
[hereinafter
CDRH
Plan
of
Action
for
510(k)
and
Science],
http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/
CDRH/CDRHReports/UCM276316.pdf.
55
510(k) and Science Report Recommendations, supra note 25, at 16.
56
Id.
57
An infusion pump is a Class II medical device intended for use in a health care facility to
pump fluids into a patient in a controlled manner. 21 C.F.R. § 880.5725 (2012).
58
CDRH Plan of Action for 510(k) and Science, supra note 54, at 1.
51
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2. Submit All Scientific Information Regarding Safety and/or Effectiveness
The 510(k) Working Group also recommended changing the statutory test of
21 C.F.R. § 807.87 to explicitly require anyone submitting a 510(k) application to
submit a list and brief description of all scientific information that is known or
should be known regarding the safety and/or effectiveness of a new device.59
Because this recommendation may become burdensome (especially if the
information is not known but would need to be discovered because it should be
known), the FDA decided to implement this recommendation on a case-by-case
basis.60 Thus, the FDA has decided to create device-specific guidance to instruct
510(k) submitters as to when they should submit information about the safety and
effectiveness of a new device. Further, they will initially only require 510(k)
submitters to submit information that is already known.61
3. Submission of Photographs and Schematics
Under the current 510(k) system, photographs and schematics are sometimes
submitted with a 510(k) application; the FDA has found this information to be
helpful in making a determination of substantial equivalence.62 The FDA
therefore decided to change the system to require the submission of detailed
photographs and schematics in order to help improve reviewer efficiency and
effectiveness.63 To effectively implement this change, the FDA held a public
meeting on April 7, 2011 to get public feedback on the change.64 The results of
this public meeting were not available at the time this article was completed.
4. Submission of Manufacturing Process Information
The CDRH already has the ability to request manufacturing information for
some devices, but there has been no clarity given about when the ability will be
used or should be used.65 The change recommended by the CDRH is to provide
greater clarity about when this right will be or should be exercised.66 The CDRH
plans on implementing this recommendation by providing guidance on when the
manufacturing information will be requested and pointing to the fact that they will
be interested in getting manufacturing information for higher-risk devices.67 This
59

510(k) and Science Report Recommendations, supra note 25, at 17.
Id.
61
Id.
62
Id. at 8.
63
Id. at 8–9.
64
CDRH Plan of Action for 510(k) and Science, supra note 54, at 1.
65
510(k) and Science Report Recommendations, supra note 25, at 19.
66
Id.
67
Id.
60
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recommendation will be initially implemented on a case-by-case basis for higherrisk devices and will be tailored to address relevant issues specific to that type of
device.68
5. Use of “Multiple Predicates”
Under the current 510(k) program, a manufacturer of a medical device can use
a “multiple predicate” or “split predicates” when claiming that its device is
substantially equivalent to an existing device.69 This means that a comparison can
be made to one existing device to show the same “intended use” while a
comparison can be made to a different existing device to show the new device’s
“technological characteristics”.70 The 510(k) Working Group recommended that
the CDRH develop guidance on the appropriate use of more than one predicate,
while at the same time exploring the possibility of explicitly disallowing the use
of “split predicates.”71 This change would mean that in order to submit a 510(k)
application that would be approved, a medical device manufacturer would have to
use the same predicate device and claim that their device is substantially
equivalent to the predicate device in terms of both intended use and technological
characteristics. At the time of this writing, the CDRH had completed a
preliminary study to review how safe and effective medical devices are when they
claim more than one predicate device.72 The CDRH’s current plan of action is to
implement guidance to clarify when it is appropriate to use multiple predicates,
while continuing to monitor what effect these changes might make.73
6. A New Subset of Class IIb Devices
One major change the FDA recommended is the creation of a new subset of
medical devices called Class IIb.74 The Class IIb devices would potentially
require that clinical information, information about manufacturing processes, and
additional evaluation in the postmarket setting be required under the 510(k)
program for a particular subset of higher risk Class II devices.75 The FDA
explains that they are not proposing a brand new class of devices. Rather they
would try to group higher-risk Class II devices under a “Class IIb” setting when
68

Id. at 19–20.
Id. at 14.
70
Id.
71
Id.
72
U.S. Food and Drug Admin., Medical Device Reporting (MDR) Rate in 510(k) Cleared
Devices
Using
Multiple
Predicates,
http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CD
RHReports/ucm275629.htm (last updated Nov. 12, 2011).
73
510(k) and Science Report Recommendations, supra note 25, at 14.
74
Id. at 17.
75
Id.
69
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filing a 510(k) application so that those device manufacturers are aware that more
information would likely be requested by the FDA before their 510(k) application
would be approved under the new guidelines.76 The FDA further explained that
there would be no clear-cut delineation between what qualified as a Class IIa or
Class IIb device.77 Rather the classification would be determined based upon
prior approved devices, and new devices would not be classified into Class IIa or
IIb until the FDA had time to meet with and talk to the submitters.78 The FDA
had not provided a timeline for implementing this recommendation at the time of
this writing.79
7. Publicly Available 510(k) Searchable Database
The 510(k) Working Group recommended that the CDRH develop a
searchable database for all verified 510(k) applications.80 It recommended that
this database include the 510(k) summary, photographs and schematics of the
device (to the extent that they do not contain proprietary information), and
information showing how the current 510(k) application is similar to its claimed
predicate device(s).81 Industry participants raised concerns about having detailed
schematics, drawings, and/or photographs available to the public because of the
increased potential for patent infringement and reverse engineering.82 The FDA
has explained that the ‘photographs or schematics’ referred to by the Working
Group is actually only one photograph or one schematic given by the 510(k)
submitter to be used in the database, thus not giving away proprietary
information.83 Due to this concern, the FDA held a public meeting on April 7,
2011 to receive public comments about this recommendation.84 At the time of
this writing, the FDA had not publically announced how it planned to proceed in
regards to photographs and schematics going forward.

76

Id. at 18.
Id.
78
Id.
79
See id. at 19.
80
Id. at 20.
81
Id.
82
Id. at 21.
83
Id. at 21.
84
U.S. Food and Drug Admin., 510(k) Implementation: Discussion of an On-line Repository of
Medical Device Labeling, and of Making Device Photographs Available in a Public Database
Without
Disclosing
Proprietary
Information,
April
7,
2011,
http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/ucm243829.htm (last
updated May 13, 2011).
77
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ISSUES WITH PATENT VALIDITY

The following section analyzes how the 510(k) application may play into the
validity of patents. As will be explained below, some courts have considered the
510(k) application materials when determining patent validity and some courts
have decided that 510(k) materials should not be allowed to play into the
determination. There is currently no binding rule about how 510(k) application
materials can or should play into determining the validity of a patent during
litigation.
A.

Elements to Consider When Determining the Validity of a New Patent

There are four different criteria that patent applications have to fulfill before
the patent application will be granted: that the invention be a new process,
machine, manufacture, or composition of matter;85 that the invention be useful;86
that the invention be novel;87 and that the invention be non-obvious.88 The
following sections evaluate how the 510(k) application may play into the
requirements of patentability and the filing of the patent application.
1. Novelty
Section 102 of the Patent Act sets out the conditions for patentability. 89
Section 102 reads in part:
A person shall be entitled to a patent unless- (a) the invention was
known or used by others in this country, or patented or described
in a printed publication in this or a foreign country, before the
invention thereof by the applicant for patent, or (b) the invention
was patented or described in a printed publication in this or a
foreign country or in public use or on sale in this country, more
than one year prior to the date of the application for patent in the
United States . . . .90

This section sets out the concept of novelty in terms of anticipation. “[I]f a device
or process has been previously invented (and disclosed to the public), then it is

85

35 U.S.C. § 101 (2006).
Id.
87
Id. § 102.
88
Id. § 103.
89
Id. § 102.
90
Id. § 102(a)–(b).
86
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not new, and therefore the claimed invention is ‘anticipated’ by the prior
invention.”91
In Johnson & Johnson Vision Care, Inc. v. CIBA Vision Corp., the plaintiffs
argued that the defendants patent was not valid because it was “anticipated.”92
This argument was founded in part on the fact that the defendant had filed a
510(k) application with the FDA for the approval of their medical device one year
before they filed their patent.93 The defendant argued that while they filed their
510(k) application over a year before they filed their patent application, the
510(k) application was not made “public” as required by § 102 because the 510(k)
application was not made public until they were within a year of filing their patent
application.94 The court held that while it was known that a 510(k) application
had been filed, it cannot, by clear and convincing evidence, show that the medical
device was known such as to anticipate the patent.95
In Arthrocare Corp. v. Smith & Nephew, Inc., the defendant tried to argue that
the 510(k) application materials that had been submitted to the FDA should have
been admitted into evidence as relevant to the issue of anticipation.96 Particularly
the defendant “charge[d] that the submissions demonstrate that the commercial
embodiments of the patents in suit have the same principles of operation as prior
art devices.”97 The court ruled that the 510(k) application materials were not
admissible as evidence, because the 510(k) submissions claimed equivalence to
commercial embodiments and not the particular claims of the asserted prior art.98
In Mentor H/S, Inc. v. Medical Device Alliance, Inc., the jury considered the
510(k) applications in their decision that every element for finding anticipation
was fulfilled.99 The district court overruled the jury’s decision and found that the
elements for anticipation were not found, but was subsequently overruled by the
Federal Circuit.100 The Federal Circuit rested their decision on the fact that the
jury’s decision was not against the great weight of the evidence.101

91

Net MoneyIN, Inc. v. VeriSign, Inc., 545 F.3d 1359, 1369 (Fed. Cir. 2008).
Johnson & Johnson Vision Care, Inc. v. CIBA Vision Corp., 634 F. Supp. 2d 1293, 1308 (D.
Fla. 2008).
93
Id.
94
Id.
95
Id. at 1310.
96
Arthrocare Corp. v. Smith & Nephew, Inc., 310 F. Supp. 2d 638, 667 (D. Del. 2004).
97
Id.
98
Id.
99
Mentor H/S, Inc. v. Med. Device Alliance, Inc., 244 F.3d 1365, 1372 (Fed. Cir. 2001).
100
Id. at 1380.
101
Id. at 1376.
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[3:160 2012] CYBARIS®, AN INTELLECTUAL PROPERTY LAW REVIEW

174

As seen from the previous decisions, the issue of whether 510(k) applications
materials should play into the finding of novelty for patent applications is not
resolved.102 Some courts have allowed the 510(k) application to go to the jury as
evidence,103 while other courts are less certain about whether or not the 510(k)
application contains relevant information for finding anticipation under § 102.104
2. Obviousness
Section 103 of the Patent Act sets out the criteria of non-obviousness for
patent applications.105 Section 103 reads in part as:
A patent may not be obtained though the invention is not
identically disclosed or described as set forth in section 102 of this
title, if the differences between the subject matter sought to be
patented and the prior art are such that the subject matter as a
whole would have been obvious at the time the invention was
made to a person having ordinary skill in the art to which said
subject matter pertains. Patentability shall not be negatived by the
manner in which the invention was made.106
As set out in Perfect Web Technologies, Inc. v. InfoUSA, Inc., a determination of
obviousness requires consideration of the “(1) the scope and content of the prior
art, (2) the differences between the prior art and the claims at issue, (3) the level
of ordinary skill in the pertinent art, and (4) secondary considerations of
nonobviousness.”107
In Johnson & Johnson Vision Care, the plaintiff also claimed that the
defendant’s patent application was obvious due to the submission of the 510(k)
application.108 It argued that the predicate devices listed in the 510(k) application
and the prior art listed on the patent application disclosed the technology in the
patent application and thus deemed the patent obvious.109 The court denied the

102

See supra notes 91, 92, 96, 99 and accompanying text.
See Mentor H/S, Inc., 244 F.3d 1365.
104
See Johnson & Johnson Vision Care, Inc. v. CIBA Vision Corp., 634 F. Supp. 2d 1293 (D.
Fla. 2008); Arthrocare Corp. v. Smith & Nephew, Inc., 310 F. Supp. 2d 638 (D. Del. 2004).
105
35 U.S.C. § 103 (2006).
106
Id. § 103(a).
107
Perfect Web Techs., Inc. v. InfoUSA, Inc., 587 F.3d 1324, 1327 (Fed. Cir. 2009) (citing
KSR Int’l Co. v. Teleflex Inc., 550 U.S. 398, 406 (2007)).
108
Johnson & Johnson Vision Care, Inc., 634 F. Supp. 2d at 1307.
109
Id. at 1317.
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defendant’s motion for summary judgment but never explicitly stated if its
decision rested upon the use of the 510(k) application materials.110
B.
Inequitable Conduct Before the United States Patent and Trademark
Office
The other issue to consider when evaluating the validity of a patent is how the
applicant conducts itself before the United States Patent and Trademark Office
(USPTO). In Mentor H/S, Inc., the district court concluded that the:
[J]ury’s verdict was against the great weight of the evidence
because [the defendant] asserted in his 510(k) application to the
FDA that his prototype was similar in design to the [substantially
equivalent device], but then failed to disclose his opinion regarding
the similarity of the products to the PTO during prosecution of the
. . . patent.111
The Federal Circuit reversed the district court’s decision on inequitable conduct
after finding that the jury’s decision was not against the great weight of the
evidence, thus finding that the defendant had not represented himself in an
inequitable manner before the USPTO.112
As evidenced in the jury’s decision in Mentor H/S, Inc. and by the panel of
Federal Circuit judge’s decision that the district court erred in ruling contrary to
the jury’s findings, the 510(k) application materials were used as evidence to
determine whether inequitable conduct before the USPTO had taken place.113
Thus, it appears as if the 510(k) application materials may sometimes be used in
considerations of inequitable conduct and that the 510(k) materials may be
submitted as evidence to the jury.
V.

INTERSECTION WITH PATENT LITIGATION

The following sections examine how the use of 510(k) application materials,
particularly the substantial equivalence claim that is made on 510(k) applications,
intersects with patent litigation. It has been decided by the Supreme Court that
the substantial equivalence claim made on 510(k) application materials is not an
admission of infringement. But there is currently no binding rule as to how
510(k) application materials may play into other considerations during patent
infringement litigation.
110

Id. at 1319 (holding that “there is sufficient evidence to create a triable issue of fact on the
issue of obviousness”).
111
Mentor H/S, Inc. v. Med. Device Alliance, Inc., 244 F.3d 1365, 1372 (Fed. Cir. 2001).
112
Id. at 1378.
113
Id. at 1365.
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Eli Lilly and Co. v. Medtronic, Inc.

Eli Lilly was decided by the Supreme Court in 1990 and analyzed the
intersection between patent infringement and the materials that are submitted to
the FDA for medical device approval.114 The Court held that the alleged
infringer’s use of a patented invention to develop and submit information for
marketing approval of medical devices under the Federal Food, Drug and
Cosmetic Act was not infringement.115 This decision was based on section 271(e)
of the Patent Act. Section 271(e) of the Patent Act states that:
It shall not be an act of infringement to make, use, offer to sell, or
sell within the United States or import into the United States a
patented invention . . . solely for uses reasonably related to the
development and submission of information under a Federal law
which regulates the manufacture, use, or sale of drugs or veterinary
biological products.116
The parties to this suit argued whether the text, which appears to apply to
pharmaceutical drugs, was intended by Congress to apply to medical devices.117
The Court ultimately held that Congress intended to extend this protection to
medical devices.118
Since this decision it has come to be widely held that substantial equivalent
claims that are made in 510(k) applications cannot be construed as admissions of
direct infringement.119 This may have lead to the general idea that 510(k)
application materials are not admissible as evidence at trial, but recent court cases
may cause some to hesitate.120 While courts still hold that the prior art used on
FDA 510(k) applications are not an admission of direct infringement,121 there
have been some recent decisions that allow the use of 510(k) materials to be
considered in patent litigation cases as supporting materials to other claims.122
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Eli Lilly & Co. v. Medtronic, Inc., 496 U.S. 661 (1990).
Id. at 668–69.
116
35 U.S.C. § 271(e)(1) (2006).
117
Eli Lilly & Co., 496 U.S. at 665.
118
Id. at 679.
119
See, e.g., Am. Med. Sys., Inc. v. Laser Peripherals, LLC, 712 F. Supp. 2d 885, 905 (D.
Minn. 2010); Sunrise Med. HHG, Inc. v. Airsep Corp., 95 F. Supp. 2d 348, 406 (W.D. Pa. 2000).
120
See, e.g., U.S. Surgical Corp. v. Hospital Prods. Int’l Pty., Ltd, 701 F. Supp. 314 (D. Conn.
1988) (allowing the admission of 510(k) materials as evidence for deciding whether infringement
has happened.).
121
See Eli Lilly & Co., 496 U.S. 661.
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See, e.g., U.S. Surgical Corp., 701 F. Supp. 314.
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Patent Infringement

Since Eli Lilly, courts have repeatedly held that the 510(k) application is not
an admission of patent infringement,123 but they have considered allowing the
510(k) to be admitted at trial as evidence in patent infringement cases. 124 This
section reviews some of the concerns that arise when considering the intersection
between the FDA’s 510(k) process and patent litigation, especially in light of the
recently proposed changes to the FDA 510(k) process.
1. Direct Infringement
Direct infringement of a patent occurs when “whoever without authority
makes, uses, offers to sell, or sells any patented invention, within the United
States or imports into the United States any patented invention during the term of
the patent . . . .”125 Courts have typically applied a two-part test to determine
whether direct infringement has occurred.126 The first step, commonly known as
claim construction, is to define the meaning and scope of the patent claims alleged
to be infringed.127 The second step is to compare those claims to the alleged
infringing device.128
In United States Surgical Corp. (USSC) v. Hospital Products International
Pty. Ltd, the plaintiff was bringing an action for infringement of its surgical
stapling device against the defendant.129 The court stated that:
[T]he defendants have gone so far as to cause statements to be
made that may be construed as admissions of infringement. For
example, on October 28, 1980, HPI submitted to the United States
Food and Drug Administration a § 510(k) pre-market notification .
. . [that] stated in the notification that these devices were
equivalent to their USSC counterparts. . . . Similarly, on November
16, 1981, SCI submitted to the FDA a second § 510(k) pre-market
notification to announce its intention to sell its ILA anastomosis
123

See, e.g., Am. Med. Sys., Inc., 712 F. Supp. 2d at 905 (citing CardioVention, Inc. v.
Medtronic, Inc., 483 F. Supp. 2d 830, 840 (D. Minn. 2007)).
124
See, e.g., U.S. Surgical Corp., 701 F. Supp. at 347.
125
35 U.S.C. § 271(a) (2006).
126
Markman v. Westview Instruments, Inc., 52 F.3d 967, 976 (Fed. Cir. 1995), aff’d, 517 U.S.
370 (1996).
127
Id. (citing Read Corp. v. Portec, Inc., 970 F.2d 816, 821 (Fed. Cir. 1992) (abrogated on
other grounds)).
128
Id. at 976. Direct infringement occurs where each limitation of at least one claim of the
patent is found exactly in the alleged infringer’s product. See, e.g., Johnston v. IVAC Corp., 885
F.2d 1574, 1577 (Fed. Cir. 1989); Panduit Corp. v. Dennison Mfg. Co., 836 F.2d 1329, 1330 n.1
(Fed. Cir. 1987).
129
U.S. Surgical Corp., 701 F. Supp. at 317.
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surgical stapling equipment. The SCI device was stated to be
“substantially equivalent” to USSC’s GIA surgical stapler . . . .130
The court ultimately held that HPI did in fact infringe upon USSC’s surgical
stapling device patents.131 This decision did not rely solely on the information
provided in the 510(k) application, but the court did consider the information
provided in the 510(k) application and allowed it to be admissible as evidence for
the plaintiff to prove that infringement had taken place.132
In contrast, the 510(k) application materials were not allowed in court to
prove direct infringement in American Medical Systems, Inc. v. Laser
Peripherals, LLC.133 In American Medical Systems, the plaintiff relied on the
defendant’s representation made to the FDA in the form of the 510(k) that
claimed its product was substantially equivalent to the plaintiff’s invention. The
court, following the majority trend, decided this was not an admission of
infringement, because substantial equivalence means something different in the
FDA context than it does in the patent infringement context.134 It appears as if the
court choose not to decide whether the 510(k) application should be admissible as
evidence on its face, but rather decided that the information would be confusing to
a jury and may distract from the litigation at hand.
A similar justification was used for not considering the 510(k) application
material in Sunrise Medical HHG, Inc. v. Airsep Corp.135 The court stated that
they placed no reliance on the 510(k) application as “[i]ts sole purpose was to
demonstrate to the FDA that the [infringing product] was as safe and effective as
the [patented invention]. That purpose was accomplished without any discussion
of the differences between the two devices . . . .”136
Courts have tended to rule that the 510(k) application materials are not
admissible as admissions of infringement, but they have yet to determine whether
the 510(k) application materials should be considered when looking at a claim for
130

Id. at 347.
Id. at 352–53. The court found that the defendant failed to prove the plaintiff’s patents were
invalid or unenforceable and that the plaintiff had proven its claim for infringement. Id.
132
Id. at 347.
133
712 F. Supp. 2d 885, 905 (D. Minn. 2010).
134
Id. at 905. The court here relied on the ruling in CardioVention, Inc. v. Medtronic, Inc., 483
F. Supp. 2d 830 (D. Minn. 2007), where the court decided in a case of patent validity that the
510(k) information was not admissible to show invalidity of a patent because admission of the
510(k) application materials would be misleading and unfairly prejudicial. CardioVention, Inc.,
483 F. Supp. 2d at 840.
135
Sunrise Med. HHG, Inc. v. Airsep Corp., 95 F. Supp. 2d 348, 406 (W.D. Pa. 2000).
136
Id. at 406. The court does not cite any other opinions regarding whether or not to consider
510(k) application materials in patent litigation. Id.
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direct infringement.
For example, the court in United States Surgical
Corporation decided to take the 510(k) application materials into account when
deciding whether direct infringement has happened,137 while the courts in
American Medical Systems, Inc., and Sunrise Medical HHG, Inc. decided not to
consider the 510(k) application materials because they did not find them
applicable to a finding of direct infringement.138 Without a precedential decision
of whether the 510(k) application materials should be admissible as evidence to
support a finding of direct infringement, companies should be careful about the
information that is included in their 510(k) applications.
2. Contributory Infringement
Contributory infringement is set out in the Patent Act in § 271(c):
Whoever offers to sell or sells within the United States or imports
into the United States a component of a patented machine,
manufacture, combination or composition, or a material or
apparatus for use in practicing a patented process, constituting a
material part of the invention, knowing the same to be especially
made or especially adapted for use in an infringement of such
patent, and not a staple article or commodity of commerce suitable
for substantial noninfringing use, shall be liable as a contributory
infringer.139
In order to establish contributory infringement the party must first establish direct
infringement.140 A panel of Federal Circuit judges has explained that contributory
infringement is premised on the idea that any defendant who has shown sufficient
culpability should be held liable, even if he was not a direct infringer and even if
he did not intend to cause or contribute to infringement.141
In United States Surgical Corporation, it was found that the defendant had
directly infringed on the plaintiff’s patents.142 The court then turned to consider
whether the defendant was liable for contributory infringement of the plaintiff’s
137

U.S. Surgical Corp., 701 F. Supp. at 347.
Am. Med. Sys., Inc., 712 F. Supp. 2d at 905; Sunrise Med. HHG Inc., 95 F. Supp. 2d at 406.
139
35 U.S.C. § 271(c) (2006).
140
Aro Mfg. Co. v. Convertible Top Replacement Co., 365 U.S. 336, 341 (1961).
141
Hewlett-Packard Co. v. Bausch & Lomb, Inc., 909 F.2d 1464, 1469 (Fed. Cir. 1990). This
has been further explained that there can be no contributory infringement without knowledge that
the component was especially adapted for a particular use in a known patent. Id.
142
U.S. Surgical Corp., 701 F. Supp. 314. United States Surgical Corporation considers the
510(k) application in their analysis of contributory infringement because they considered the
510(k) application in their analysis of direct infringement and found that the patents had been
directly infringed upon. Id.
138
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patents. The court ruled that the defendant was liable for contributory
infringement, and again the 510(k) application was considered as evidence in
considering contributory infringement and was not disallowed.143
3. Infringement Under the Doctrine of Equivalents
“An accused device that does not literally infringe a claim may still infringe
under the doctrine of equivalents if each limitation of the claim is met in the
accused device either literally or equivalently.”144 The doctrine of equivalents can
be applied in cases of patent infringement where each element of a claim is not
literally infringed, but rather where the difference between the infringing product
and the claimed limitation are insubstantial to someone who posses an ordinary
skill in the particular art.145 A panel of Federal Circuit judges has cautioned that
courts may not compare the accused product with the commercial embodiment of
the patented invention, but it must be compared to the claims that exist
individually in the patent.146
University of Florida Research Foundation, Inc. v. Orthovita shows how the
510(k) application materials may have a role in determining infringement by
equivalents.147 In University of Florida Research Foundation, Inc., the plaintiffs
made a claim for infringement by equivalence, which they planned to prove in
part by submitting the 510(k) application materials as evidence of infringement by
equivalence.148 The court found that the “FDA submission [is] fatally deficient in
that [it] compare[s] the accused [infringing product], not to the patent claims, but
to the commercial embodiment of the patentee’s invention . . . .”149 Relying on
the advice of the Federal Circuit,150 the court decided that the 510(k) application
materials were not suitable as evidence because they did not compare the alleged
infringed product to the patent claims but rather to the commercial product.151
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Id. at 350.
Cybor Corp. v. FAS Techs., Inc., 138 F.3d 1448, 1459 (Fed. Cir. 1998) (citing WarnerJenkinson Co. v. Hilton Davis Chem. Co., 520 U.S. 17, 39–41 (1997); Pennwalt Corp. v. DurandWayland, Inc., 833 F.2d 931, 935 (Fed. Cir. 1987) (en banc)).
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See Warner-Jenkinson Co., Inc. v. Hilton Davis Chem. Co., 520 U.S. 17, 25 (1997) (citing
Graver Tank & Mfg. Co., Inc., v. Linde Air Products Co., 339 U.S. 605, 609 (1950)).
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Zenith Labs. v. Bristol Myers Squibb Co., 19 F.3d 1418, 1423 (Fed. Cir. 1994).
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No. 1:96-CV-82-MMP, 1998 WL 34007129, at *23 (N.D. Fla. Apr. 20, 1998).
148
Id.
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Id.
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patented invention must be made to the individual patent claims and not to the commercial
product. Zenith Labs., 19 F.3d at 1423.
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Similar to the case of direct infringement, the court has not ruled whether the
510(k) application materials should be allowed as evidence of infringement by
equivalence. Rather the court decided not to consider the 510(k) application
materials on the grounds that they compared the infringing device to the available
commercial product and not the patent claims. Without a precedential ruling on
this matter, the same concerns arise in light of considering how a 510(k)
application may play into patent litigation in the future.
4. Willful and Deliberate Conduct
Medical device companies may view what happened in United States Surgical
Corporation as a warning of how the 510(k) application materials could affect
their patent infringement litigation.152 If a court finds that an infringer acted
willfully and deliberately they “may increase the damages up to three times the
amount found or assessed.”153 In order to determine whether the infringer acted
in bad faith the court should consider the elements set out in Bott v. Four Star
Corp.:
(1) [W]hether the infringer deliberately copied the ideas or design
of another; (2) whether the infringer, when he knew of the other’s
patent protection, investigated the scope of the patent and formed a
good-faith belief that it was invalid or that it was not infringed, and
(3) the infringer’s behavior as a party to the litigation.154
In United States Surgical Corporation, the 510(k) application materials were
considered as evidence in finding direct and contributory infringement.
Furthermore, all evidence that was submitted for the finding of infringement was
considered in determining whether there was a finding of willful and deliberate
conduct.155 The court decided that the evidence that was made available
throughout the course of the trial did show willful and deliberate conduct. This
evidence included the 510(k) application materials that had been presented
throughout the course of the trial.156
While the 510(k) application was not conclusive for the finding of willful and
deliberate conduct it was considered as a piece of the evidence that eventually
lead to that finding. Medical device producers should be aware of this decision
152

U.S. Surgical Corp., 701 F. Supp. 314.
35 U.S.C. § 284 (2006); see Beatrice Foods Co. v. New England Printing & Lithographing
Co., 923 F.2d 1576, 1579 (Fed. Cir. 1991) (finding that enhanced damages may be awarded in
patent infringement action only as penalty for infringer's increased culpability, namely willful
infringement or bad faith).
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Bott v. Four Star Corp., 807 F.2d 1567, 1572 (Fed. Cir. 1986).
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U.S. Surgical Corp., 701 F. Supp. at 351.
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when they decide what information should be included in their 510(k)
applications.
C. Validity of Resulting Patent
In CardioVention, Inc. v. Medtronic, Inc., the court ruled that 510(k) materials
were not admissible at trial to determine validity of patents. 157 In CardioVention,
both parties brought motions in limine. The plaintiff was seeking a declaration
that the defendant’s patents were invalid or unenforceable, and the defendant
requested that the court exclude any evidence concerning its listing of the
plaintiff’s device as a predicate device on its 510(k) application to the FDA.158
The court ruled that the
Admission of the 510(k) evidence would be misleading and unfairly
prejudicial to Medtronic. It would also cause undue delay and a
waste of time because the parties would litigate the meaning of the
FDA regulatory system and the difference between that and the
standards for the claims before the jury.159
The court further stated that the fact that the two inventions in question were
substantially equivalent, as defined in terms of the FDA, was not the same as if
they were determined substantially equivalent in the trade secret context.160
Ultimately the court ruled that “[e]ven if the notification is some slight evidence
of similarity between the [infringing device] and the [patented invention], this
relevance is substantially outweighed by the danger of confusion, of misleading
the jury, of undue delay, and of waste of time.”161
In CardioVention, the court decided that the 510(k) application materials were
not admissible as evidence in determining the invalidity or unenforceability of the
plaintiff’s patents because the 510(k) application materials would be misleading
to the jury.162 The court based this decision on the majority trend to not allow
510(k) application materials into patent infringement litigation, as it is widely
held that the substantial equivalence claim on the 510(k) application is not an
admission of infringement.

157

CardioVention, Inc. v. Medtronic, Inc., 483 F. Supp. 2d 830, 840 (D. Minn. 2007).
Id. at 834. Plaintiff also asserted claims of breach of contract, misappropriation of trade
secrets, unfair competition, and intentional interference with prospective economic advantage. Id.
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Id. at 840.
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Id.
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Id. at 841.
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Id. at 840.
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ANALYSIS OF HOW THE FDA 510(K) PROCESS MAY AFFECT PATENT
LITIGATION MOVING FORWARD

Patent law and regulatory law are both important things to consider when
developing and marketing medical devices. Medical device manufacturers must
be able to protect their invention while at the same time getting FDA approval of
their invention. Patent law and regulatory law go hand-in-hand in this aspect, as a
medical device manufacture cannot market his device without first getting FDA
approval. At the same time they have to weigh the benefit of patenting a device,
sometimes before the FDA has approved the device. Because of the pairing of
these two areas of law in medical device manufacturing, it is important to
consider the policy justifications behind both systems.
The FDA is charged with “promot[ing] the public health by promptly and
efficiently reviewing clinical research and taking appropriate action on the
marketing of regulated products in a timely manner.”163 Further, the FDA is
intended to protect the public health by ensuring that there is a reasonable
assurance of the safety and effectiveness of devices that are intended for human
use.164 In comparison, the widely cited justification for the patent system is to
promote innovation while at the same time giving the public access to new
technologies.165 This justification for the patent system works because people
disclose their inventions to the USPTO, which puts the technology in the hands of
any person wanting to access it, and in turn the patent owner gets the right to
exclude others from using the invention for a period of twenty years.
When considering the policy justifications of both systems, it appears as if
there are some similarities between the two. One main similarity is that both
systems are based on the general idea that they are concerned with helping the
general public. There is also a similarity in the fact that both have an underlying
goal of promoting innovation. The FDA claims to do this by regulating the health
field, which helps alleviate consumers’ concerns about new drugs and devices.
The patent system claims to do this by rewarding inventors so they disclose their
inventions.
One question that remains unanswered is whether the policy justifications of
the two systems need to be similar to work efficiently together. It is arguable that
they do not have to have the same policy justifications to work well together, but
that it would make things easier for medical device manufacturers if they did.
More specifically, it may not matter so much whether the underlying policy goals
163
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are perfectly aligned but whether the two systems have similar goals moving
forward.
A. Analysis of How the Changes to the 510(k) System Will Affect Patent
Validity
Courts have not agreed whether the 510(k) application should be admissible
as evidence in determining the validity of patents, as evidenced in the above-cited
decisions.166 Thus, it is important for medical device manufacturers to be aware
of what information they are releasing in their 510(k) applications. As evidenced
by the decision in Mentor H/S, Inc.,167 it is also important for medical device
manufactures to consider what information they disclose to the USPTO, as the
510(k) application materials can be used in considering whether inequitable
conduct has taken place.
When considering the changes that are being made to the 510(k) process, it is
important to think about how this may affect patent validity questions. The
proposed change to switch the 510(k) application to be based upon an assurance
case framework means that manufacturers will need to state detailed claims about
the effectiveness and safety of their device.168 It also means that incomplete
510(k) applications will not be looked at. The result of this change will be that
510(k) applications will need to include a more detailed description of a device
and its intended use, which means there is potentially more information available
that can be used in evaluating patent validity. This information may be
admissible if the patent application is filed more than a year after the 510(k)
application is submitted (concerning novelty) or if there is a claim of infringement
(as a party defending against an infringement case could use a more detailed
analysis to prove that the patent was anticipated or obvious and thus invalid).
There are also changes proposed that would require a medical device
manufacturer to submit more specific information with their 510(k) application.169
These changes include: providing scientific evidence, providing photographs and
schematics, and providing manufacturing process information. This additional
information that may be required may also be used to point to the fact that a
claimed invention is anticipated or obvious.
The major concern that arises when comparing the changes to the 510(k)
system with the patent process is related to the publicly available database.170
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Under the current system only the 510(k) summary is made public when a device
is approved through the 510(k) process.171 The proposed change to the 510(k)
system would include photographs, schematics, or drawings published with every
510(k) application that has been approved, as well as information regarding how
the current device is similar to the claimed predicate device.172 The concern that
arises under this situation in relation to patent validity is whether submitting the
510(k) application would be considered a disclosure of the invention. While one
has a year window in which to file their patent application after the disclosure of
their invention,173 publishing a more comprehensive 510(k) summary on the FDA
website could lead to trouble for those who fail to file their patent application in a
timely fashion. There is currently no binding precedential rule that states whether
or not the 510(k) application can be used as a means of showing that the device
was anticipated or obvious.174 Publishing more detailed 510(k) applications in a
publically searchable database may prove to be problematic until it is determined
how the 510(k) application may play into determining the validity of a patent.
B. Analysis of How the Changes to the 510(k) System May Affect Patent
Litigation
In light of the changes that are being made to the 510(k) system, medical
device companies will also need to be especially aware of how the information in
their 510(k) application may play into patent litigation cases.
The concern that arises out of the switch to an assurance case framework 175 is
that because medical device manufacturers will be required to give a more
detailed description of how their device is similar to the predicate device they are
claiming, it may lead to more findings of patent infringement. Courts have
typically held that the 510(k) application materials are not admissible as evidence
in patent litigation cases because the FDA’s definition of a ‘substantial
equivalent’ is different than the definition of a ‘substantial equivalent’ in a patent
context.176 But if a manufacturer is required to provide a detailed claim of how
their device is similar to the substantial equivalent, the later courts may follow the
171
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decision in United States Surgical Corporation and allow the 510(k) application
materials into cases considering patent infringement.177
The changes that will require more information to be given in the 510(k)
application (providing scientific evidence, providing photographs and schematics,
and providing manufacturing process information)178 may also have the same
effect on patent litigation. That is, with more detailed information being disclosed
in the 510(k) application, more courts may be likely to consider the 510(k)
application materials in patent litigation cases.
There is also a concern that having to provide more detailed information will
cause problems with people infringing devices claimed on 510(k) applications
that may be published in the 510(k) database.179 Providing photographs or
schematics to the general public, along with more detailed 510(k) summaries,
may cause issues with reverse engineering. While the FDA claims confidential
information will still be kept confidential,180 there is a concern that the increase in
the amount of information that is given to the FDA through the 510(k) process
may lead to more problems. More detailed information about the intended use of
a device and more detailed information about how the current device is
substantially equivalent to the claimed predicate device, paired with photographs
or schematics, may lead to more problems than predicted.
Considering the formation of a new class of devices, Class IIb devices, the
same concerns arise.181 Class IIb device 510(k) applications are going to be
required to have more detailed information submitted, including the three changes
listed above.182 Devices that are classified as Class IIb devices are going to have
larger hurdles to overcome in order to get their 510(k) approval, which in turn
means a lot more information will be released. This raises a lot of concern about
how this information may lead to others reverse engineering the devices and/or
how the information released under the 510(k) application may play into future
patent litigation.
Another concern arises out of the limited use (or potential elimination) of
using multiple predicates on a 510(k) application.183 If a party is held to only
claim substantial equivalence to one device there may be a greater link drawn
between the technological characteristics of the current device and the claimed
177
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predicate device. Again, there may be a situation where the courts follow the idea
in United States Surgical Corporation and allow these materials to be submitted
in patent infringement cases due to the higher level of information being disclosed
and the more direct link being made between the two devices.184
As the 510(k) system gets more rigorous there is uncertainty about how it will
affect the area of patent law. Since the Eli Lilly decision, it has been widely held
that the substantial equivalence claimed in the 510(k) application cannot be held
as an admission of direct infringement.185 But there is currently no binding ruling
that is widely held as precedent on how 510(k) application materials can play into
other aspects of patent litigation. And until there is a binding ruling or statutory
language spelling it out, medical device manufacturers need to be especially
aware of what information they are releasing in their 510(k) applications to the
FDA.
VII.

CONCLUSION: HOW INVENTORS MAY PROTECT THEMSELVES UNDER THE
NEW 510(K) STRUCTURE

Medical device manufacturers would be wise to be very careful with the
information they disclose in their 510(k) applications moving forward. They have
two main options moving forward. The first will be to supply all information the
FDA asks for in great detail to ensure that their 510(k) application is approved in
a timely manner. If this first approach is taken it will be important for medical
device manufactures to be aware of how the information they are releasing may
be used in determining the validity of their patent application or how the
information may play into future patent infringement claims. The second option
is to release as little information as necessary under the new changes. The danger
in choosing this option is that the CDRH may decide it is not sufficient and the
medical device manufacturers may be asked for additional materials, which could
slow down the approval of their device for marketing.
While neither choice is a good option, medical device companies may be
better protected by trying to release only the information that is necessary, taking
the risk that it may slow down the approval of their device for market. This
approach is the best strategy for medical device manufacturers until there is
statutory language or a binding ruling defining exactly how 510(k) application
materials may play into patent litigation.
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